- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 436174, 6 pages
Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo
1Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 00 Prague, Czech Republic
2Institute of Pathology, First Faculty of Medicine, Charles University in Prague, 128 00 Prague, Czech Republic
3Department of Obstetrics and Gynaecology, University Hospital Brno, 625 00 Brno, Czech Republic
4Department of Obstetrics and Gynaecology, Second Faculty of Medicine, Charles University in Prague, 150 06 Prague, Czech Republic
Received 7 March 2012; Revised 18 May 2012; Accepted 18 May 2012
Academic Editor: Faustino R. Pérez-López
Copyright © 2012 Petr Horak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aim. To determine if hormonal treatment induces apoptosis in uterine fibroids. Methods. Immunohistochemical examination of fibroid tissue, using avidin-biotin complex and cleaved caspase-3 antibody for detecting apoptosis, was performed in premenopausal women who underwent 12-week treatment with oral SPRM (6 patients with 5 mg and 5 patients with 10 mg of ulipristal acetate per day) or gonadoliberin agonist (GnRHa, 17 patients) and subsequent myomectomy or hysterectomy for symptomatic uterine fibroids. Ten patients with no presurgical hormonal treatment were used as controls. Results. Apoptosis was present in a significantly higher proportion of patients treated with ulipristal acetate compared to GnRHa () and to patients with no hormonal treatment (). In contrast to an AI of 158.9 in SPRM patients, the mean AI was 27.5 and 2.0 in GnRHa and control groups, respectively. No statistical difference in the AI was observed between the two groups of patients treated with ulipristal acetate (5 mg or 10 mg). Conclusion. Treatment with ulipristal acetate induces apoptosis in uterine fibroid cells. This effect of SPRM may contribute to their positive clinical effect on uterine fibroids.
Uterine fibroids are the most common benign gynecological tumors. Their prevalence in premenopausal patients is 30–40%, making them one of the most common reasons for gynecological surgery .
The etiology and pathophysiology are still unknown. It is considered that various genetic, anthropometric, racial, reproductive, and vascular factors, as well as the role of growth factors or some hormones, particularly ovarian steroids, could play a role [2–7].
Surgery still dominates fibroid treatment; the most common is myomectomy or hysterectomy depending on the age and reproductive status of the patient. Nowadays, pharmacological intervention is used as a symptomatic therapy in smaller fibroids. There are few drugs that have the potential to have a direct effect on fibroid growth. The most promising in this category are the selective progesterone receptor modulators (SPRMs) that have become the subject of intense investigation in recent years but have not yet been introduced into standard clinical practice. The mechanism of action of these drugs is still unknown but the effect on myoma-related symptoms and fibroid shrinkage was proven in early clinical studies [8, 9]. Their selective antiproliferative, proapoptotic, and antifibrinolytic effect on fibroids has been demonstrated in human tissue cultures in vitro . The aim of our study was to determine the eventual higher apoptosis rate in fibroids extirpated from patients given SPRM pretreatment compared with controls.
2. Materials and Methods
2.1. Patient Recruitment
Patients with uterine fibroids were given ulipristal acetate (PGL4001) during 12 weeks prior to the planned surgery. This drug, provided by PregLem S.A., Switzerland, belongs to the SPRM group. These patients had participated in a phase III clinical study with ulipristal acetate. This study, in which patients received daily dose of 5 or 10 mg of ulipristal acetate or placebo, evaluated the efficacy of ulipristal acetate on symptomatic uterine fibroids . Patients that received active treatment and required surgery for their fibroids were included in the present study.
For a comparable group, we chose patients with symptomatic fibroids who were treated with gonadoliberin agonist (GnRHa) triptorelin (Ipsen Pharma Biotech, France) 12 weeks prior to planned surgery at a dose of 3 mg intramuscularly 3 times at 28-day intervals. For controls we enrolled patients with the same diagnosis who were receiving no hormonal pretreatment and were referred to have either a hysterectomy or myomectomy. The operation was always scheduled within 2 weeks from the last SPRM dose or 6 weeks within the last dose of GnRHa.
Our study did not have a randomized or double-blind design. Patient recruitment into each group was dependant on a patient informed choice. In order to reduce anemia and the risk of perioperative blood transfusion and if patients met the inclusion criteria (see below), they were given the option of 12 weeks of hormonal pretreatment with ulipristal acetate (as part of the multicenter placebo-controlled study with SPRM) or triptorelin. If the patients preferred early surgery with no hormonal treatment, they were included in the control group. Patients were fully informed of all known advantages, disadvantages, and differences between the two options of treatment including the fact that if patients choose the SPRM, they could be randomized into the placebo subgroup.
All the patients in the study were administered oral iron supplements (Ferrous sulphate 80 mg once daily) starting either with the administration of hormonal treatment (both groups with hormonal pretreatment) or on the day of the enrolment in the study (control group).
2.2. Inclusion and Exclusion Criteria
Patients aged between 18 and 50 years of age with uterine fibroid/s sized ≥3 cm (the largest measurable diameter of myoma measured by vaginal ultrasonography prior to ulipristal or triptorelin administration or before surgery in the control group), typical myoma-related symptoms (menorrhagia with PBAC (Pictorial Bleeding Assessment Chart) score higher than 100 for the 1st–8th days of menstruation; eventually pressure pelvic symptoms) [12, 13] and significant anemia (hemoglobin ≤ 100 g/L) were included in the study.
Exclusion criteria were patients with an overall size of uterus exceeding 16th week of pregnancy, history of uterine surgery, hormonal supplement therapy and hormonal contraception administration or other hormonal treatment with estrogen or progesterone within the last month prior to the study, BMI ≤ 18 or ≥40, hemoglobinopathy, atypical hyperplasia or endometrial carcinoma, cervical cancer, ovarian or breast cancer, endometrial polyp larger than 2 cm, and ovarian cyst larger than 4 cm. Patients who refused to sign the informed consent and patients who, regardless of the reasons, wanted to terminate their participation in the study were also excluded. We also excluded women whose histological examination of the extirpated tumor of the uterus or the entire uterus brought a different result than vital (therefore evaluable) leiomyoma and patients (from the study of PregLem S.A.) that used placebo instead of ulipristal acetate.
The study protocol was approved by the Ethics Committee of the first Medical Faculty of Charles University in Prague. All patients enrolled signed an informed consent.
2.3. Laboratory Examination of Fibroids, and Statistical Analysis
All study women who underwent myomectomy (open or laparoscopic) or hysterectomy (laparoscopically assisted vaginal or open) were subject to standard histological examination of the removed myoma or the entire uterus and immunohistochemical tests to detect apoptosis. These examinations were performed and evaluated by the same pathologist who was not informed of whether the patient received any hormonal therapy prior to the surgery.
Immunohistochemistry was performed using the avidin-biotin complex method with antibody against cleaved caspase-3 (dilution 1 : 250, Cell Signaling Technology, Beverly, MA). Antigen retrieval was performed with a sodium citrate buffer (pH 6.0) in a water bath for 40 minutes. The apoptotic index (AI), the number of apoptotic cells of all cells counted, was determined manually using an ocular counting grid at three randomly chosen fields. One thousand cells for each sample were counted [14, 15].
We used a nonparametric Kruskal-Wallis test and Mann-Whitney test (with the Bonferroni adjustment of P values for multiple testing) for statistical comparison of the results of the AI between the subgroups (SPRM versus GnRHa, SPRM versus controls, GnRHa versus controls, and SPRM 10 mg versus SPRM 5 mg). For comparison between patients with an AI higher than 10, a chi-square test and Fisher test were used.
A total of 41 symptomatic patients who met the inclusion criteria were recruited to our study between November 2008 and December 2009. Out of these 41 patients, 17 patients preferred GnRHa and 10 patients requested an early operation with no pretreatment. In the placebo-controlled study with ulipristal acetate 14 patients were included, of which 3 patients were subsequently excluded following the unblinding of data revealing placebo administration. Uterine fibroids from the remaining 38 patients were examined histologically after surgery and immunohistochemical tests were performed to detect apoptosis. The baseline characteristics of each group are summarized in Table 1. Patients in each group did not significantly differ in age, BMI, size of dominant fibroid or parity. All the histological findings revealed conventional leiomyomata.
Based on the results of immunohistochemistry, an AI was calculated for each patient. Zero or minimal percentage (less than 1% of 1000 cells examined) of cells with apoptosis were detected in 18.2% of patients receiving preoperative SPRM compared to 76.5% of patients receiving GnRHa and 100% in the control group. The differences between SPRM versus GnRHa (, test) and SPRM versus controls (, Fisher’s test), respectively, were statistically significant (see Table 2). The highest average AI value was described in the SPRM group (157.9), which was significantly higher than that in GnRHa group (27.5; ) and the control group (2.0; ). The results of each single patient including detailed comparison of the subgroups are shown in Figure 1 and Table 2.
We also tried to determine if there was any difference in the incidence of apoptosis between patients with different doses of ulipristal as well as if a dose-dependent apoptosis rate in the SPRM group could be found (Table 3). In our limited group of 11 patients, we did not observe a higher proportion of cells with apoptosis in women receiving a higher dose of SPRM (, Mann-Whitney test).
Uterus-sparing therapy remains an up-to-date topic even in cases of women no longer desiring pregnancy. Myomectomy remains the most frequently used surgical technique. There is a constant search for alternatives to myomectomy because this operation is both quite invasive for the patient and risky and devastating for the uterus before planned pregnancy. Apart from occlusive methods aimed at fibroid devascularization (uterine artery embolization (UAE), and laparoscopic uterine artery occlusion (LUAO)) new modalities such as thermoablation of fibroids by focused ultrasound or radiofrequency ablation are beginning to be used [16–19].
None of the above-stated methods, however, affect pathophysiology of fibroids or have systematic effects. Some hormonal drugs have the potential to treat the cause of the disease. Many drug groups, such as progesterone (including intrauterine application), Danazol, gonadoliberin agonists and antagonists, selective estrogen receptors modulators, aromatase inhibitors, or antiprogesterone, have been used in this indication [20–25]. None of the drugs have made a significant breakthrough in fibroid treatment.
GnRHa is the most used and studied to date. These drugs cause hypoestrinism, which, after several months of use, leads to a slight fibroid volume reduction [15, 26]. The use of GnRHa is unfortunately accompanied with a number of drawbacks, which is why their use in the treatment of fibroids has been limited to three-month pretreatment in selected patients before myomectomy or hysterectomy [27–29].
Fibroid cells demonstrate higher concentration of estrogen receptors compared to surrounding myometrium, equally higher expression of mRNA and of progesterone receptors (PRs) A and B. Increase of mitotic activity and fibroid size in the secretory phase of the cycle has also been described [30–32]. Therefore, the logical effort is to use drugs not only causing hypoestrinism but also affecting PR. In addition to antiprogesterone, Mifepristone, an SPRM, may become one of the drugs used in fibroid treatment [33, 34], due to their targeted mode of action. Unlike Mifepristone, which apart from reduction of menorrhagia and reduction of uterine and fibroid volume leads to hyperplasia of the endometrium, SPRM with its modified both agonistic and antagonistic PR effect does not have this undesirable effect on the endometrium [35, 36]. SPRMs act directly on the endometrium by maintaining its glandular and stromal proliferation at low levels and thus causing amenorrhea in most of the patients without causing hypoestrinism. Similar morphological changes, as well as a reduction in mitotic activity, were detected in cells of leiomyomas examined after hysterectomy of 33 patients receiving 12-weeks treatment with asoprisnil prior to the surgery .
In cell cultures SPRMs lead to reduction of cell viability, suppression of expression of growth factors and induced apoptosis through mitochondrial activation and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) . Bcl-2 is considered to be the key protein in the inhibition of apoptosis. It has been demonstrated that a Bcl-2 promoter interacts with PR by progesterone, suggesting in what other ways SPRMs may induce apoptosis . But the proapoptotic effect of an SPRM has not yet been verified in vivo. Asoprisnil (J867) is a typical example of the SPRM, which selectively induces apoptosis in leiomyomas cells in tissue cultures without causing proliferation or apoptosis in normal cells of the myometrium [10, 40]. In our study, we used ulipristal acetate (PGL 4001 or CDB-2914, 17alpha-Acetoxy-11beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione), a steroid substance reversibly blocking progesterone receptors. Despite the limited number of patients in the study we observed a significantly higher apoptosis rate in fibroid cells exposed to ulipristal acetate preoperatively compared to fibroids of patients treated with GnRHa as well as in fibroids with no preoperative hormonal treatment. Apoptosis may thus be an important, although apparently not the only, mechanism of an SPRM suppression effect on uterine fibroids. The other factor may be, for instance, uterine artery flow reduction . However, our results should not be generalized to all preparations that modify PR because the group of SPRMs seems to be heterogeneous. The fact that the apoptosis rate was not significantly higher using twice the daily dose of ulipristal acetate (10 mg) suggests that a daily dose of 5 mg ulipristal acetate is sufficient for apoptosis induction and a higher dose apparently does not increase its proapoptotic effect. Unfortunately, at the moment we cannot say if longer use of ulipristal acetate like 6 or 12 months could lead to even larger proapoptotic effect in fibroids or not.
Apoptosis is one of the main types of programmed cell death. It incorporates a series of biochemical processes leading to typical changes in cell appearance. This process is then followed by removal of the cells (without inflammation), making apoptosis in the foundations different from necrosis. The borderline between apoptosis and necrosis is however not clear and sometimes both processes combine making the designation of the cell death ambiguous . The following laboratory methods are used in apoptosis detection: phosphatidylserine-annexin V, DNA fragmentation (ELISA), Laddering, TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling), Fas, TNFR1, and P53 . In our study, we used the method of indirect immunohistochemistry with cleaved caspase-3 antibody (Figure 2). We used an avidin-biotin complex (ABC method) technique with visualization using horseradish peroxidase and diaminobenzidine.
Selective proapoptotic and antiproliferative effects of SPRM preparations could be the ideal mechanism for suppression of uterine fibroids with a permanent or at least longer effect compared to GnRHa without adverse events of hypoestrinism, concurrently with much safer results than the necrosis caused by the UAE. Their big clinical potential (cessation of excessive uterine bleeding, correction of severe anemia, and volume reduction of the fibroids and the uterus) and safety in women with fibroids have been recently proved by two large randomized trials [11, 43]. On the other hand the necrosis after UAE, which can also occur inside the uterine cavity, can greatly reduce the chances for patients to have a successful pregnancy and that is why UAE is considered to be relatively contraindicated in patients planning pregnancy [44–46].
A study by Korean authors comparing occlusive methods in uterine fibroid treatment was targeted at apoptosis detection. Fibroids extirpated 6 months after occlusive treatment were examined with the following results: while the typical finding in fibroids with acute ischemia caused by UAE was necrosis, in cases after LUAO it was apoptosis . In 8 patients, we also examined fibroids removed following LUAO, which was performed within the previous year and had little effect on both fibroid volume reduction and symptoms. These fibroids were examined with the same technique as in all patients in our study. We did not observe a significant apoptosis rate in these 8 patients, the average AI was 19.3 and thus lower than in women treated with GnRHa. However, in all 8 patients, the occlusive treatment failed and was performed in a longer interval prior to myomectomy (and examination for apoptosis), which could have substantially affected the results.
We can summarize that the three-month pre-operative administration of ulipristal acetate induced natural cell death in uterine fibroids in premenopausal women. On the other hand, in women who had three months of preoperative administration of GnRH analogues or no hormonal therapy, a significantly lower proportion of apoptotic cells in leiomyomas were observed.
This study was supported by a grant IGA NS 9798-4 from the Ministry of Health of the Czech Republic.
- E. E. Wallach and N. F. Vlahos, “Uterine myomas: an overview of development, clinical features, and management,” Obstetrics and Gynecology, vol. 104, no. 2, pp. 393–406, 2004.
- A. Arici and I. Sozen, “Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-β1 in human myometrium and leiomyoma,” American Journal of Obstetrics and Gynecology, vol. 188, no. 1, pp. 76–83, 2003.
- L. M. Marshall, D. Spiegelman, R. L. Barbieri et al., “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race,” Obstetrics and Gynecology, vol. 90, no. 6, pp. 967–973, 1997.
- T. Maruo, H. Matsuo, Y. Shimomura et al., “Effects of progesterone on growth factor expression in human uterine leiomyoma,” Steroids, vol. 68, no. 10–13, pp. 817–824, 2003.
- I. Sozen and A. Arici, “Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors,” Obstetrics and Gynecology Clinics of North America, vol. 33, no. 1, pp. 41–58, 2006.
- J. R. Toro, M. L. Nickerson, M. H. Wei et al., “Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America,” American Journal of Human Genetics, vol. 73, no. 1, pp. 95–106, 2003.
- C. L. Walker, “Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma,” Recent Progress in Hormone Research, vol. 57, pp. 277–294, 2002.
- L. K. Nieman, W. Blocker, T. Nansel et al., “Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study,” Fertility and Sterility, vol. 95, no. 2, pp. 767.e2–772.e2, 2011.
- J. Wilkens, K. Chwalisz, C. Han et al., “Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4664–4671, 2008.
- W. Chen, N. Ohara, J. Wang et al., “A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1296–1304, 2006.
- J. Donnez, T. F. Tatarchuk, and P. Bouchard, “Ulipristal acetate versus placebo for fibroid treatment prior to surgery,” The New England Journal of Medicine, vol. 366, no. 5, pp. 409–420, 2012.
- J. M. Higham, P. M. S. O'Brien, and R. W. Shaw, “Assessment of menstrual blood loss using a pictorial chart,” British Journal of Obstetrics and Gynaecology, vol. 97, no. 8, pp. 734–739, 1990.
- C. A. H. Janssen, P. C. Scholten, and A. P. M. Heintz, “A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss,” Obstetrics and Gynecology, vol. 85, no. 6, pp. 977–982, 1995.
- K. D. Burroughs, R. Fuchs-Young, B. Davis, and C. L. Walker, “Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat,” Biology of Reproduction, vol. 63, no. 5, pp. 1322–1330, 2000.
- K. N. Khan, M. Kitajima, K. Hiraki et al., “Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy,” Human Reproduction, vol. 25, no. 3, pp. 642–653, 2010.
- W. M. Liu, “Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic leiomyomas,” Journal of the American Association of Gynecologic Laparoscopists, vol. 7, no. 1, pp. 125–129, 2000.
- J. H. Ravina, D. Herbreteau, N. Ciraru-Vigneron et al., “Arterial embolisation to treat uterine myomata,” The Lancet, vol. 346, no. 8976, pp. 671–672, 1995.
- C. Recaldini, G. Carrafiello, D. Laganà et al., “Percutaneous sonographically guided radiofrequency ablation of medium-sized fibroids: feasibility study,” American Journal of Roentgenology, vol. 189, no. 6, pp. 1303–1306, 2007.
- E. A. Stewart, W. M. W. Gedroyc, C. M. C. Tempany et al., “Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique,” American Journal of Obstetrics and Gynecology, vol. 189, no. 1, pp. 48–54, 2003.
- S. H. Eisinger, S. Meldrum, K. Fiscella, H. D. Le Roux, and D. S. Guzick, “Low-dose mifepristone for uterine leiomyomata,” Obstetrics and Gynecology, vol. 101, no. 2, pp. 243–250, 2003.
- N. Chegini, C. Ma, X. M. Tang, and R. S. Williams, “Effects of GnRH analogues, “add-back” steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-β expression,” Molecular Human Reproduction, vol. 8, no. 12, pp. 1071–1078, 2002.
- T. Maruo, N. Ohara, H. Matsuo et al., “Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas,” Contraception, vol. 75, no. 6, pp. S99–S103, 2007.
- D. L. Olive, S. R. Lindheim, and E. A. Pritts, “Non-surgical management of leiomyoma: impact on fertility,” Current Opinion in Obstetrics and Gynecology, vol. 16, no. 3, pp. 239–243, 2004.
- B. W. Rackow and A. Arici, “Options for medical treatment of myomas,” Obstetrics and Gynecology Clinics of North America, vol. 33, no. 1, pp. 97–113, 2006.
- M. Shozu, K. Murakami, T. Segawa, T. Kasai, and M. Inoue, “Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor,” Fertility and Sterility, vol. 79, no. 3, pp. 628–631, 2003.
- V. De Leo, G. Morgante, A. La Marca et al., “A benefit-risk assessment of medical treatment for uterine leiomyomas,” Drug Safety, vol. 25, no. 11, pp. 759–779, 2002.
- A. Golan, I. Bukovsky, M. Pansky, D. Schneider, Z. Weinraub, and E. Caspi, “Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata,” Human Reproduction, vol. 8, no. 3, pp. 450–452, 1993.
- A. Lethaby, B. Vollenhoven, and M. Sowter, “Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review,” An International Journal of Obstetrics and Gynaecology, vol. 109, no. 10, pp. 1097–1108, 2002.
- I. Manyonda, E. Sinthamoney, and A. M. Belli, “Controversies and challenges in the modern management of uterine fibroids,” An International Journal of Obstetrics and Gynaecology, vol. 111, no. 2, pp. 95–102, 2004.
- J. Fujimoto, S. Ichigo, M. Hori, M. Nishigaki, and T. Tamaya, “Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors,” Tumor Biology, vol. 16, no. 4, pp. 254–260, 1995.
- S. Chrapusta, W. Sieinski, B. Konopka, J. Szamborski, and Z. Paszko, “Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle,” European Journal of Gynaecological Oncology, vol. 11, no. 5, pp. 381–387, 1990.
- K. Kawaguchi, S. Fujii, I. Konishi, Y. Nanbu, H. Nonogaki, and T. Mori, “Mitotic activity in uterine leiomyomas during the menstrual cycle,” American Journal of Obstetrics and Gynecology, vol. 160, no. 3, pp. 637–641, 1989.
- D. DeManno, W. Elger, R. Garg et al., “Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy,” Steroids, vol. 68, no. 10–13, pp. 1019–1032, 2003.
- A. A. Murphy, A. J. Morales, L. M. Kettel, and S. S. C. Yen, “Regression of uterine leiomyomata to the antiprogesterone RU486: dose- response effect,” Fertility and Sterility, vol. 64, no. 1, pp. 187–190, 1995.
- M. Bagaria, A. Suneja, N. B. Vaid, K. Guleria, and K. Mishra, “Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 49, no. 1, pp. 77–83, 2009.
- J. Wilkens, A. R. W. Williams, K. Chwalisz, C. Han, I. T. Cameron, and H. O. D. Critchley, “Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN,” Human Reproduction, vol. 24, no. 5, pp. 1036–1044, 2009.
- A. R. W. Williams, H. O. D. Critchley, J. Osei et al., “The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata,” Human Reproduction, vol. 22, no. 6, pp. 1696–1704, 2007.
- T. Maruo, N. Ohara, S. Yoshida et al., “Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system,” Contraception, vol. 82, no. 5, pp. 435–441, 2010.
- P. Yin, Z. Lin, Y. H. Cheng et al., “Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4459–4466, 2007.
- S. Yoshida, N. Ohara, Q. Xu et al., “Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth,” Seminars in Reproductive Medicine, vol. 28, no. 3, pp. 260–273, 2010.
- K. M. Martel, A. C. Ko, G. M. Christman, and J. M. Stribley, “Apoptosis in human uterine leiomyomas,” Seminars in Reproductive Medicine, vol. 22, no. 2, pp. 91–103, 2004.
- W. R. Duan, D. S. Gamer, S. D. Williams, C. L. Funckes-Shippy, I. S. Spath, and E. A. G. Blomme, “Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts,” Journal of Pathology, vol. 199, no. 2, pp. 221–228, 2003.
- J. Donnez, J. Tomaszewski, and F. Vázquez, “PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids,” The New England Journal of Medicine, vol. 366, pp. 421–432, 2012.
- Committee on Gynecologic Practice, American College of Obstetricians, and Gynecologists: ACOG Committee Opinion, “Uterine artery embolization,” Obstetrics & Gynecology, vol. 103, pp. 403–404, 2004.
- D. Kuzel, M. Mara, P. Horak et al., “Comparative outcomes of hysteroscopic examinations performed after uterine artery embolization or laparoscopic uterine artery occlusion to treat leiomyomas,” Fertility and Sterility, vol. 95, no. 6, pp. 2143–2145, 2011.
- H. Homer and E. Saridogan, “Uterine artery embolization for fibroids is associated with an increased risk of miscarriage,” Fertility and Sterility, vol. 94, no. 1, pp. 324–330, 2010.
- K. H. Park, J. Y. Kim, J. S. Shin et al., “Treatment outcomes of uterine artery embolization and laparoscopic uterine artery ligation for uterine myoma,” Yonsei Medical Journal, vol. 44, no. 4, pp. 694–702, 2003.